used: total tau (T-tau), phosphorylated tau (P-tau) and A ␤ 42. T-tau is hypothesized to reflect the rate of neuronal degeneration, and high P-tau and low A ␤ 42 correlates with the formation of tangles and plaques, respectively [3, 6] ; although 2 recent studies showed no correlation between CSF tau and neocortical tangle pathology [7, 8] . Discrepant quantities of CSF AD markers have been found in DLB; however, the overall trend is towards values somewhere between AD and DLB [9] [10] [11] , and whether the CSF AD markers predict earlier death among clinically diagnosed DLB patients, has not been studied.
The authors of this article recently demonstrated a disturbed trace element homeostasis in DLB patients, with a robust and specific increase in CSF calcium (Ca) and magnesium (Mg) compared to both controls and AD patients [12] . These results hint at a possible pathogenic or disease-modifying role of divalent ions in the DLB patients' juxtaneuronal environment.
In order to explore the influence of concomitant AD pathology and CSF trace elements on the disease course, we undertook a study of the commonly used CSF biomarkers for AD as well as the CSF metal concentrations as possible determinants of survival in clinically diagnosed DLB. The mortality rate of people with dementia is known to increase with age [13] . This is undoubtedly connected to the mortality rate according to age in a population in general. Thus, we included a control group of healthy volunteers to obtain a more specific picture of the influences of AD and DLB on mortality, and the determinants thereof.
The primary aim of this study was to explore the CSF levels of AD-associated bio-markers and CSF metal concentrations as determinants of survival among DLB patients.
Method and Material
Forty-seven DLB and 157 AD patients admitted to the Neuropsychiatry Clinic, University Hospital MAS, Malmö, between 1999 and 2003 were included in a longitudinal prospective study. All patients who had completed a full investigation, together with their primary caregiver, were included. The diagnosis was continuously clinically reevaluated, and at the end of the study, the patients fulfilled the 2005 consensus criteria for probable DLB [1, 14] , or the clinical criteria for AD (NINCDS-ADRDA) [15] . In addition, 49 healthy volunteers were included. All the study subjects were followed for a maximum of 7 years.
The study subjects underwent a baseline investigation of their medical history, physical and neurological examination, CT of the brain, measurement of the relative cerebral blood flow, and cognitive function (MMSE) [16] . Furthermore, CSF and plasma samples were collected. CSF T-tau, P-tau and A ␤ 42 concentrations were measured with the xMAP technology and an INNO-BIA AlzBio3 kit (Innogenetics, Gent, Belgium) as described by Olsson et al. [17] .
The total concentrations in CSF of Mg, Ca, and copper (Cu) were determined by inductively coupled plasma mass spectrometry (Thermo X7; Thermo Elemental, Winsford, UK) in accordance with Gerhardsson et al. [18] .
This study was approved by the ethics committee of the University of Lund and carried out in accordance with the Helsinki Declaration.
Statistical Analysis SPSS 16.0 was used for the statistical analyses. To avoid a bias of nonnormal distributions, the Mann-Whitney U test was used to analyze differences between the AD and the DLB groups with respect to demographic data. Kaplan-Meier survival curves were constructed to estimate the survival distributions between the groups, and the generalized Wilcoxon test was used to compare these survival distributions. Cox proportional hazard models were used to determine the effects of covariates on survival time. In order to determine the influence of covariates on mortality, 2 Cox regression analyses were performed with backward removal, with a removal limit of p = 0.10. The first analysis comprised CSF biomarkers of AD pathology, i.e. T-tau, P-tau and A ␤ 42, as well as the possible confounding factors age, MMSE score at baseline and gender. The second regression analysis comprised CSF Ca, Mg and Cu concentrations.
Results
Demographic data, cognitive status at baseline and a comparison between groups of the analyzed covariates are presented in table 1 . Comparably more male patients were present in the DLB group than among the controls and the AD patients. There was a tendency towards a higher rate of cognitive decline among the DLB patients compared to the AD patients; however, this trend did not reach significance (Mann-Whitney U test; p = 0.08).
Both the DLB and AD groups had a markedly shorter survival compared to controls (relative risk: 8 and 10, respectively; p ! 0.001 in both cases). There was a trend towards younger age at death in DLB compared to AD (p = 0.08) ( fig. 1 ). Furthermore, there was a nonsignificant tendency towards increased mortality during follow-up in the DLB group compared to the AD group when the disease duration was calculated from the first contact with the specialist clinic (p = 0.13) ( fig. 2 ) .
The multivariate Cox proportional hazard model revealed that DLB patients with elevated levels of CSF T-tau had an increased risk of early death (p = 0.022; hazard ratio = 1.36 per 100 ng/l T-tau; 95% CI = 1.05-1.78; model significance: p = 0.036). However, this was not the case among the AD patients or controls. Gender, age, MMSE score, P-tau concentration and A ␤ 42 concentration did not influence survival in the obtained model. A higher baseline CSF T-tau was observed among the DLB patients who were deceased compared to those that survived at follow-up (Mann-Whitney U test; p = 0.024).
The method used was insufficient to construct a Cox regression model of the influence of metal covariates on survival (with p ^ 0.05) for any of the groups.
Discussion
This is the first study to analyze the influence of CSF markers on survival among DLB patients. This study included patients with clinically probable DLB according to the consensus criteria [1] . Although a postmortem examination is required to make a certain diagnosis, the high specificity (86%) [19] of the diagnostic criteria produced a representative DLB group. This study included more male than female DLB patients, a trend seen in most studies of DLB. However, gender did not influence mortality in any of the groups studied.
The main finding of this study was that an elevated level of CSF T-tau was associated with earlier death among DLB patients, but not among AD patients or healthy controls. Furthermore, in contrast to earlier studies, the CSF T-tau levels of the DLB patients were not increased compared to the control subjects [9, 10] . To our knowledge, there is no study of the intraindividual variance of T-tau in DLB. However, CSF T-tau seems to be remarkably stable over time in both subjects with minor cognitive impairment and with AD [20, 21] . Thus, it is more likely that CSF T-tau reflects the nature than the stage of the disease. A possible explanation of the association between earlier death and elevated CSF T-tau could be that increased Ttau in the DLB group reflects concomitant AD pathology, which is known to increase mortality among DLB patients [4] . Furthermore, the T-tau concentration in CSF may reflect the intensity of neuronal degeneration in the DLB group, as is thought to be the case in all chronic neurodegenerative disorders. Thus, CSF T-tau is sometimes referred to as a 'state' marker of neurodegenerative disorders. This argument is largely based on comparisons between different brain diseases such as Creutzfeld-Jakob disease, in which both the rate of neuronal damage and T-tau are very high, compared to AD where both are comparably lower [22] . T-tau is also a dynamic marker of traumatic brain injury [23] , and the magnitude of the tau elevation is related to clinical outcome [24] . In addition, one earlier small study (n = 21) suggests an association between mortality and CSF T-tau in AD [25] . However, the present and comparably larger study (AD: n = 159) failed to demonstrate a correlation between T-tau and mortality among the AD patients. Thus, although the hypothesis on T-tau as a marker of the aggressiveness of neurodegenerative dementias could explain the main finding of this study, it needs further testing.
CSF Mg and Ca have been demonstrated to be specifically increased among DLB patients compared to AD patients and controls [12] . The results of the present study implicate that these changes may not correlate with the disease stage or rate of disease progression. However, these results must be interpreted with care due to the small sample size. Furthermore, even if the disease progression is not affected by CSF trace elements, CSF metal changes may yet be a crucial 'trigger' factor in the development of the disease. Another possibility is that CSF Ca and Mg are increased due to DLB-specific disease processes, but neither influence the development nor the course of the disease.
Both AD and DLB are associated with shorter survival, both in this study as well as in earlier studies [13, [26] [27] [28] . There was, however, no significant difference in survival time between the AD and DLB patients in the present study. This result stands in contrast to an earlier and larger study in which DLB patients had a shorter survival, but showed similar cognitive decline [4] . However, in contrast to the present study, which comprised clinically diagnosed patients, the DLB diagnosis was made post mortem, making the studies not entirely compatible.
In the DLB group, there was a tendency towards a more rapid MMSE decline as well as a trend towards a shorter survival (not significant), measured as time to death after the first contact with a specialist clinic. This Color version available online Color version available online may signal a later debut, but a more aggressive course of the disease. Thus, further and larger studies are needed to explore the mortality and rate of cognitive decline in clinically diagnosed DLB. The disease onset is measured in most clinical trials of dementia disorders. It is, however, an elusive concept, prone to recall biases on the part of patients and informants, and to a lack of understanding that certain symptoms may represent dementia. Although an earlier report suggests a good interrater reliability of the standardized estimation of disease onset [29] , the most important problem is that there is no gold standard for evaluating the validity of proxy or patient reports. Another difficulty is to decide what symptoms to look for as signs of disease onset. For instance, subjective memory problems often present years after anamnestic REM sleep behavior disorder in DLB. To avoid the subjective and elusive concept of estimated disease onset, we used the date of admission as an objective surrogate.
In summary, this study shows that CSF T-tau, a marker of AD and neuronal degeneration, is associated with increased mortality in DLB, and that CSF metal concentrations may not influence the disease progression in DLB.
